Fate Therapeutics

Fate Therapeutics Terminates Phase 1 FT538 Trial for Advanced Solid Tumors: Strategic Implications for NK-Cell Immunotherapy

Fate Therapeutics has terminated its Phase 1 clinical trial (NCT05069935) for FT538, an allogeneic NK-cell immunotherapy targeting advanced solid tumors. This sponsor-initiated decision, effective September 2023, impacts the development of novel oncology treatments. Procurement and business development teams should reassess Fate Therapeutics' pipeline and monitor the broader NK-cell therapy landscape for strategic adjustments and emerging opportunities.